OrSense launches new non-invasive hemoglobin and blood oximetry measurement deviceIsraeli company OrSense, which develops monitors for non-invasive measurements of various blood parameters, will launch its new multi-parameter sensor for non-invasive continuous hemoglobin, low signal oximetry and pulse rate measurements on March 26th in Belgium.
The NBM-200MP operates via a ring-shaped sensor that is fitted on the patient’s finger and applies a gentle pressure, temporarily occluding the blood flow. During the occlusion optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. Called Occlusion Spectroscopy, this method provides a quick, accurate and painless measurement of the patient’s blood constituent, while greatly improving patient comfort, eliminating infection risk, and providing the caregiver with superior accuracy and immediate results.
OrSense is based in Ness Ziona. Investors include Israel Health Care Ventures and STAR Ventures. The company’s monitor has been granted CE approval.